gilead report sales/earn provid busi updat
investor compani comfort beat opco sales/earn
consensu expect execut commerci financi develop
prioriti believ current ceo leav high note hope
transit new ceo smooth product sale mostli
stronger expect letairi loe gener yet biktarvi
truvada standout make slightli weak yescarta non-
gaap opex continu tightli control main late-stag pipelin
project filgotinib ra selonsertib nash approach critic readout
next two four quarter despit ceo uncertainti compani set well
current team place cfo cso new etc experienc one
provid good support counsel new ceo note
steadi hand cfo sterl financi manag margin still better
peer-group median period product stress hcv acquisit kite
pharma personnel turnov old guard
steadfast view sales/earn trough year
lag letairi revenu gener entri could make
assert trickier becom tougher comp viread ranexa
also late respect combin sale
three pressur increas hiv franchis
yescarta revenu vs consensu weaker
expect us ramp continu apac biktarvi hiv franchis continu
fire cylind increasingli sound confid sustain hiv
franchis long term hiv capsid inhibitor area
concern longer term-ori investor
recent comment strength data filgotinib
manta studi nda file need demonstr
consist dose depend seen report
thrombosi pulmonari embol pe opportunist infect filgotinib
believ investor overlook selonsertib late-stag nash
readout respect
median surviv patient rel
patient nevertheless higher risk death rel highlight
import one-stag improv diseas score patient
medicin area unmet medic
need gilead portfolio product
pipelin investig drug
includ treatment hiv/aid liver
inflammatori
respiratori diseas cardiovascular
analyst certif import disclosur see disclosur
initi coverag gilead perform rate
sinc launch hcv product late
share roller coaster ride
street first underappreci potenti hcv
surpris franchis declin worst-off patient
cure hcv busi stabil near term resurg
hiv busi growth addit kite axi-cel nash
off-set flat sales/non-gaap ep
opco model averag rel peer-group metric
believ risk/reward balanc
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
phase data pbc yescarta
follow-up data tirabrutinib phase combo data r/r cll
phase data nash
selonsertib phase data nash
phase data cle sjogren syndrom
complet list catalyst exhibit
hcv sale trough next one two year stable/up
patient diagnos treat
hiv busi outperform expect
axi-cel us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
axi-cel us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
statement million except per opcovariancenet product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share inc
product hcv hiv total products- selonsirtib- total total product perform na
exhibit descovi ftc/taf -base regimen total us hiv prescript volum
indicationdrugtimingmilestonehivvesatolimod phase studi hiv capsid phase phase data prephematology/oncologyyescarta axicabtagen enrol phase follow data enrol phase indol nhl phase combo enrol phase studi line dlbcl enrol phase phase pediatr phase studi enrol phase studi anti-bcma car-t registr studi base phase enrol phase studi mage solid ind tcr target solid endpoint phase combo studi r/r cllotherremdesivir phase studi ebola survivorsnash pbc psc stellar phase data stellar phase data fxr data pbccombin data atla phase studi selonsertib and/or and/or patient advanc fibrosi due enrol select phase studi phase finch studi phase finch studi divers studi enrol crohn phase studi cutan lupu phase studi sjogren syndrom perform na
vosevi- hcv vemlidy- biktarvy- hiv total yescarta- selonsirtib- total total product inc
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax perform na
